Our June Newsletter
Welcome to the SOPHiA GENETICS June 2024 newsletter! The past month has been filled with exciting advancements and collaborations. From launching our global consortium SOPHiA UNITY to groundbreaking partnerships with Microsoft and NVIDIA, we are pushing the boundaries of data-driven medicine.
?? Launching SOPHiA UNITY
We are excited to announce the launch of SOPHiA UNITY , a global collective intelligence network aimed at accelerating cancer research, drug development, and data-driven patient care.
We are proud to announce 纪念斯隆-凯特琳癌症中心 as the first member of SOPHiA UNITY.
“SOPHiA UNITY will bring together best-in-class institutions committed to oncology research and data-driven medicine, generating insights to further our shared goal,” said Jurgi Camblong , PhD., CEO and Co-founder.
Dive into Jurgi Camblong’s insightful article on how this groundbreaking global consortium fulfills a long-term vision.
Announcing A Groundbreaking Collaboration
SOPHiA GENETICS has teamed up with 微软 and 英伟达 to develop a streamlined, scalable, and comprehensive whole genome analytical solution. This cutting-edge WGS application will be designed to fully analyze whole genome insights within the same day, empowering researchers and clinicians to make rapid, data-driven decisions.
“Whole-genome sequencing has the potential to enhance and accelerate treatment plans and drug development efforts,” said George Vacek , Global Head of Genomics Alliances, NVIDIA. “Powered by NVIDIA #Parabricks, SOPHiA DDM? can process whole genomes in minutes, unlocking new possibilities and helping drive meaningful impact for patients worldwide.”
“We are confident our new WGS application will help provide an answer to existing customer needs and expedite research, diagnosis, and treatment planning worldwide,” said Abhimanyu Verma , Chief Technology Officer, SOPHiA GENETICS.
Explore the SOPHiA DDM? Integrated Access Mode
Our innovative solution allows you to tap into certified sequencing partners and a library of over 50 applications, covering key biomarkers from oncology to rare and inherited disorders and beyond.
Our partners generate the sequencing data and securely upload it to your SOPHiA DDM? account for analysis and reporting, while you maintain full control of all your data.
Key benefits include accuracy, efficiency, and security - watch the video to learn more!
领英推荐
Read New HRD Studies
We are excited to share two new studies on HRD assessment. Gemelli Hospital has published results using a prototype copy number variant (CNV) algorithm to support in-house homologous recombination deficiency (HRD) assessment.
This study identified a false positive multiplex ligation-dependent probe amplification (MLPA) result in an HRD-positive individual with ovarian cancer, contributing to the advancement of precision oncology research.
Additionally, a new multi-center study coordinated by the IRCCS Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy , Napoli, Italy, has been published in the European Journal of Cancer. The study provides insights into the harmonization of in-house commercial assays for HRD assessment, based on a retrospective analysis of ovarian cancer samples.
Learn more about the Gemelli study, and about the IRCCS study.
Alamut? Visual Plus Customer Spotlight
Check out our latest Alamut? Visual Plus Spotlight featuring Katherine Lafferty, MS, CGC , Sr. Clinical Genomic Variant Analyst at Broad Clinical Labs .
Katherine shares her experience on how Alamut? Visual Plus helps her overcome various variant interpretation challenges she encounters in her daily work. Her insights highlight the tool's effectiveness in improving the accuracy and efficiency of genomic analyses, making a significant impact on patient care.
Read the full spotlight to discover Katherine's experience and how Alamut? Visual Plus can enhance your variant interpretation workflow.
Success at ESHG and ASCO
Both ESHG and ASCO were resounding successes for SOPHiA GENETICS ! We had the pleasure of meeting with customers and industry leaders, showcasing our newly launched liquid biopsy solution and the dynamic SOPHiA DDM? Platform. Our team engaged in insightful discussions and shared how SOPHiA DDM? predictive insights can revolutionize multimodal digital health data.
Thank you to everyone who visited our booths and participated in our talks. Stay tuned for more exciting updates from these events and discover how SOPHiA GENETICS continues to push the boundaries of data-driven medicine.
If you're as passionate about transforming healthcare as we are, don't miss out on our future updates. ?? Subscribe to our monthly newsletter and stay at the forefront of data-driven medicine.